Boston Partners grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,523,864 shares of the biopharmaceutical company's stock after purchasing an additional 505,906 shares during the quarter. Gilead Sciences makes up approximately 0.8% of Boston Partners' portfolio, making the stock its 29th biggest position. Boston Partners owned 0.53% of Gilead Sciences worth $970,367,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. Client 1ST Advisory Group LLC raised its stake in Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 69 shares during the last quarter. Bfsg LLC boosted its holdings in Gilead Sciences by 7.7% in the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company's stock worth $149,000 after acquiring an additional 72 shares in the last quarter. Grove Bank & Trust grew its stake in shares of Gilead Sciences by 1.2% in the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company's stock worth $946,000 after acquiring an additional 74 shares during the last quarter. Wilkerson Advisory Group LLC grew its stake in shares of Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 78 shares during the last quarter. Finally, Somerset Trust Co increased its holdings in shares of Gilead Sciences by 1.0% during the second quarter. Somerset Trust Co now owns 7,778 shares of the biopharmaceutical company's stock valued at $983,000 after acquiring an additional 80 shares in the last quarter. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $168.98 on Thursday. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The stock has a market capitalization of $209.59 billion, a PE ratio of -53.47 and a beta of 0.35. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The firm's 50 day moving average price is $156.37 and its 200-day moving average price is $142.23.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts' expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company's revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.47 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences's dividend payout ratio (DPR) is -103.80%.
Trending Headlines about Gilead Sciences
These are some of the GILD headlines that stood out recently:
- Neutral Sentiment: Gilead completed a new research center in Foster City, adding specialized laboratory capacity that may support research over time, but carries no stated immediate financial impact. Article: Research center completion
- Negative Sentiment: Barclays reaffirmed its Hold rating and cited a $160 price target, indicating limited upside at the share levels referenced in recent coverage. That cautious stance may weigh on sentiment. Article: Barclays reaffirms Hold rating
- Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares, and insider Johanna Mercier sold 28,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which makes them less informative as signals about near-term company prospects, but insider sales can still add modest pressure to sentiment. Article: CFO share sale
Wall Street Analysts Forecast Growth
GILD has been the subject of several recent analyst reports. Weiss Ratings raised shares of Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, September 14th. Scotiabank increased their price target on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a "sector outperform" rating in a report on Friday, October 30th. Barclays raised their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the company an "equal weight" rating in a research report on Monday. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Finally, Morgan Stanley boosted their price target on Gilead Sciences from $163.00 to $183.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $171.63.
Check Out Our Latest Stock Report on GILD
Insider Buying and Selling
In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the sale, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. This trade represents a 20.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 102,619 shares of Gilead Sciences stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the transaction, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,632,794.28. This trade represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 237,709 shares of company stock valued at $39,799,137 in the last 90 days. Corporate insiders own 0.30% of the company's stock.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.